Compound atlas
Sexual health

PT-141

Also known as · Bremelanotide · Vyleesi

PeptidePrescription drug
Half-life
2.7h
approx. mean t½
Dose range
0.5–2 mg
typical, not prescriptive
Category
Sexual health
primary use-case
Single-dose decay
t½ = 2.7h · first-order model
~10.8h
to clear
1× t½
50%
remaining
2× t½
25%
remaining
~4× t½
6%
remaining
0%25%50%75%100%0m2.7h5.4h8.1h10.8h13.5h

How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.

Overview

A melanocortin-receptor agonist approved (Vyleesi) for low sexual desire; acts on the brain rather than vasculature.

Mechanism of action

Activates central MC4 receptors to increase sexual arousal independent of blood-flow pathways.

Typical protocol

0.5–2 mg subQ 45+ min before activity; nausea and flushing are common.

Storage

Reconstituted: refrigerated, ~30 days.

Disclaimer

This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.